VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

VJVirtual | NICE approves acalabrutinib for CLL in the UK

Toby Eyre, MD, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), Oxford University Hospitals NHS Foundation Trust, Oxford, UK, talks on the NICE approval of the Bruton’s tyrosine kinase inhibitor acalabrutinib for patients with chronic lymphocytic leukemia (CLL) in the UK, commenting on implications for clinical practice. Dr Eyre reports that the biggest impact of the approval will be in the front-line setting. Dr Eyre also highlights the approval of venetoclax in combination with obinutuzumab for patients with CLL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter